GENinCode (LON:GENI) Shares Down 5.3% – Here’s What Happened

GENinCode Plc (LON:GENI)’s stock price dropped 5.3% during trading on Tuesday . The company traded as low as GBX 0.85 and last traded at GBX 0.90. Approximately 11,692,215 shares changed hands during trading, an increase of 84% from the average daily volume of 6,365,636 shares. The stock had previously closed at GBX 0.95.

GENinCode Stock Performance

The business’s fifty day simple moving average is GBX 1.11 and its 200-day simple moving average is GBX 1.48. The firm has a market cap of £6.68 million, a P/E ratio of -0.39 and a beta of 0.59. The company has a current ratio of 0.93, a quick ratio of 15.88 and a debt-to-equity ratio of 117.74.

GENinCode (LON:GENI) last issued its quarterly earnings data on Monday, June 8th. The company reported GBX (2.08) EPS for the quarter. The firm had revenue of GBX 308 million for the quarter. GENinCode had a negative net margin of 185.47% and a negative return on equity of 409.40%. As a group, sell-side analysts expect that GENinCode Plc will post -7.1299999 earnings per share for the current year.

GENinCode Company Profile

GENinCode Plc is a UK based company specialising in genetic risk assessment of cardiovascular disease. Cardiovascular disease is the leading cause of death and disability worldwide.

GENinCode operates business units in the UK, in the United States through GENinCode U.S. Inc and in Europe through GENinCode S.L.U.

GENinCode predictive technology provides patients and physicians with globally leading preventative care and treatment strategies. GENinCode CE marked invitro-diagnostic molecular tests combine clinical algorithms and bioinformatics to provide advanced patient risk assessment to predict disease onset.